Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness (Q43765254)

26 November 2017

title

Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness (English)

1 reference

26 November 2017

0 references

Costa Pinel B

1

1 reference

26 November 2017

Belmonte Serrano M

2

1 reference

26 November 2017

Páez Vives F

3

1 reference

26 November 2017

Sabaté Obiol A

4

1 reference

26 November 2017

Estopá Sánchez A

5

1 reference

26 November 2017

Borrás Borrás J

6

1 reference

26 November 2017

publication date

1 August 2001

1 reference

26 November 2017

published in

Revista Clínica Española

1 reference

26 November 2017

volume

201

1 reference

26 November 2017

issue

8

1 reference

26 November 2017

page(s)

448-454

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

The economics of pharmacotherapy for diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Replacing insulin injections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Resource utilization and costs of care in the diabetes control and complications trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Insulin analogues and their potential in the management of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Automated, quantitative, low-pressure, cation-exchange chromatography of haemoglobin variants on midget columns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Negative consequences of glycation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Metabolic and immunologic effects of insulin lispro in gestational diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Optimal administration of lispro insulin in hyperglycemic type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Cost Implications of Wastage of Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

The action profile of lispro is not blunted by mixing in the syringe with NPH insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

A risk-benefit assessment of conventional versus intensive insulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Hypoglycemia and insulin analogues: is there a reduction in the incidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Prevention and treatment of hypoglycaemia unawareness in type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

The effects of treatment on the direct costs of diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2565%2801%2970877-6

10.1016/S0014-2565(01)70877-6

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference